These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 29066973)

  • 21. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Italiano A; Bui B
    Bull Cancer; 2008 Jan; 95(1):107-16. PubMed ID: 18230576
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
    Motzer RJ; Escudier B; Gannon A; Figlin RA
    Oncologist; 2017 Jan; 22(1):41-52. PubMed ID: 27807302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Corrigendum: From Resistance to Sensitivity: Insights and Implications of Biphasic Modulation of Autophagy by Sunitinib.
    Abdel-Aziz AK; Abdel-Naim AB; Shouman S; Minucci S; Elgendy M
    Front Pharmacol; 2018; 9():101. PubMed ID: 29485136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants.
    Zhao J; Quan H; Xu Y; Kong X; Jin L; Lou L
    Cancer Sci; 2014 Jan; 105(1):117-25. PubMed ID: 24205792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC; Wu CE; Chen JS; Tseng JH; Chiang KC; Liu YY; Tsai CY; Cheng CT; Chen TW; Jan YY; Yeh TS; Chen YY; Yeh CN
    Anticancer Res; 2014 Sep; 34(9):5029-36. PubMed ID: 25202087
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.
    Van Looy T; Gebreyohannes YK; Wozniak A; Cornillie J; Wellens J; Li H; Vanleeuw U; Floris G; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Sarcoma Res; 2014; 4():10. PubMed ID: 25132955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
    Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to?
    Kikuchi H; Hiramatsu Y; Kamiya K; Morita Y; Sakaguchi T; Konno H; Takeuchi H
    Transl Gastroenterol Hepatol; 2018; 3():14. PubMed ID: 29682621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LIX1 Controls MAPK Signaling Reactivation and Contributes to GIST-T1 Cell Resistance to Imatinib.
    Ruiz-Demoulin S; Trenquier E; Dekkar S; Deshayes S; Boisguérin P; Serrano C; de Santa Barbara P; Faure S
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary mutations of c-KIT contribute to acquired resistance to imatinib and decrease efficacy of sunitinib in Chinese patients with gastrointestinal stromal tumors.
    Gao J; Tian Y; Li J; Sun N; Yuan J; Shen L
    Med Oncol; 2013 Jun; 30(2):522. PubMed ID: 23456621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients.
    Mohammadi M; Jansen-Werkhoven TM; Ijzerman NS; den Hollander D; Bleckman RF; Oosten AW; Desar IME; Reyners AKL; Steeghs N; Gelderblom H
    Target Oncol; 2022 Nov; 17(6):627-634. PubMed ID: 36374447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma.
    Goodman VL; Rock EP; Dagher R; Ramchandani RP; Abraham S; Gobburu JV; Booth BP; Verbois SL; Morse DE; Liang CY; Chidambaram N; Jiang JX; Tang S; Mahjoob K; Justice R; Pazdur R
    Clin Cancer Res; 2007 Mar; 13(5):1367-73. PubMed ID: 17332278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors.
    Kikuchi H; Setoguchi T; Miyazaki S; Yamamoto M; Ohta M; Kamiya K; Sakaguchi T; Konno H
    Int J Clin Oncol; 2011 Dec; 16(6):741-5. PubMed ID: 21394667
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autophagy plays an important role in sunitinib-mediated cell death in H9c2 cardiac muscle cells.
    Zhao Y; Xue T; Yang X; Zhu H; Ding X; Lou L; Lu W; Yang B; He Q
    Toxicol Appl Pharmacol; 2010 Oct; 248(1):20-7. PubMed ID: 20637791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic Renal Cell Carcinoma Rapidly Progressive to Sunitinib: What to Do Next?
    Bersanelli M; Iacovelli R; Buti S; Houede N; Laguerre B; Procopio G; Lheureux S; Fischer R; Negrier S; Ravaud A; Oudard S; Escudier B; Albiges L; Porta C
    Eur Urol Oncol; 2021 Apr; 4(2):274-281. PubMed ID: 31331862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
    Adenis A; Blay JY; Bui-Nguyen B; Bouché O; Bertucci F; Isambert N; Bompas E; Chaigneau L; Domont J; Ray-Coquard I; Blésius A; Van Tine BA; Bulusu VR; Dubreuil P; Mansfield CD; Acin Y; Moussy A; Hermine O; Le Cesne A
    Ann Oncol; 2014 Sep; 25(9):1762-1769. PubMed ID: 25122671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD; Reichardt P; Kang YK; Blay JY; Rutkowski P; Gelderblom H; Hohenberger P; Leahy M; von Mehren M; Joensuu H; Badalamenti G; Blackstein M; Le Cesne A; Schöffski P; Maki RG; Bauer S; Nguyen BB; Xu J; Nishida T; Chung J; Kappeler C; Kuss I; Laurent D; Casali PG;
    Lancet; 2013 Jan; 381(9863):295-302. PubMed ID: 23177515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of post-first-line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta-analysis.
    Hu K; Zhang H; Shu M; Wang X
    Cancer Med; 2023 Jun; 12(11):12187-12197. PubMed ID: 37084005
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib malate for gastrointestinal stromal tumour in imatinib mesylate-resistant patients: recommendations and evidence.
    Younus J; Verma S; Franek J; Coakley N;
    Curr Oncol; 2010 Aug; 17(4):4-10. PubMed ID: 20697509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors.
    Valle JW; Faivre S; Hubner RA; Grande E; Raymond E
    Cancer Treat Rev; 2014 Dec; 40(10):1230-8. PubMed ID: 25283354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.